Patents Represented by Attorney Michael C. Sudol
  • Patent number: 4835138
    Abstract: Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities.
    Type: Grant
    Filed: May 18, 1987
    Date of Patent: May 30, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Jose Alexander, A. J. Repta, Joseph A. Fix
  • Patent number: 4833168
    Abstract: There are disclosed novel avermectin compounds wherein the glycosyl side chain is substituted with, or replaced by an alkyl ester group in a Reformatsky reaction. The compounds are prepared by reacting an .alpha.-halogenated ester to a 4'-, 4"- or 13-keto-avermectin derivative in the presence of a reducing agent. The avermectin compounds have utility as anti-parasitic agents and compositions for that use are also disclosed. The compounds are also highly potent insecticides against agricultural pests.
    Type: Grant
    Filed: October 3, 1986
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Matthew J. Wyvratt, Jr.
  • Patent number: 4832957
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.
    Type: Grant
    Filed: July 25, 1988
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Patent number: 4831017
    Abstract: Novel method of increasing litter size in monogastric domestic animals by administering an avermectin or milbemycin compound during mid-gestation.
    Type: Grant
    Filed: June 29, 1987
    Date of Patent: May 16, 1989
    Assignee: Merck & Co., Inc.
    Inventor: John R. Egerton
  • Patent number: 4831035
    Abstract: Certain substituted hexahydroarylquinolizines and pharmaceutically acceptable salts thereof are peripherally selective .alpha..sub.2 -adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.
    Type: Grant
    Filed: July 27, 1987
    Date of Patent: May 16, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Joel R. Huff, Susan J. deSolms, Joseph P. Vacca, Jonathan M. Wiggins, Steven D. Young
  • Patent number: 4831016
    Abstract: There are disclosed novel avermectin reduction products. The compounds are prepared by selective catalytic hydrogenation of avermectin-like compounds or by reaction of selected double bonds with electrophylic reagents. The reduced avermectin compounds have utility as anti-parasitic agents and compositions for that use are also disclosed. The compounds are also highly potent insecticides against agricultural pests. The reduced avermectin compounds have increased stability towards light which prolongs their insecticidal activities when applied to field crops subject to irradiation by sunlight.
    Type: Grant
    Filed: October 31, 1986
    Date of Patent: May 16, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Helmut Mrozik, Thomas L. Shih
  • Patent number: 4824849
    Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, platelet aggregation inhibitors, antiobesity agents, and modifiers of gastrointestinal motility.
    Type: Grant
    Filed: August 28, 1987
    Date of Patent: April 25, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Joel R. Huff, Joseph P. Vacca, Steven D. Young, Jane deSolms, James P. Guare, Jr.
  • Patent number: 4822773
    Abstract: Choline ester salts are used as drug absorption enhancing agents for orally and rectally administered drugs.
    Type: Grant
    Filed: December 20, 1987
    Date of Patent: April 18, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Jose Alexander, Joseph A. Fix
  • Patent number: 4820818
    Abstract: The muscle relaxant (E)-3-(9-chloro-5,6-dihydro-11H-pyrrolo[2,1-b][3]benzazepin-11-ylidene-N,N -dimethyl-1-propanamine is prepared by the geometric stereoselective dehydration of the intermediate carbinol with acidic agents and organic bases and low temperatures.
    Type: Grant
    Filed: May 2, 1988
    Date of Patent: April 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ruth V. Wattley, Gerard R. Kieczykowski
  • Patent number: 4820848
    Abstract: Aromatic sulfonamides with a saturated heterocycle fused thereto are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.
    Type: Grant
    Filed: April 4, 1988
    Date of Patent: April 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Ponticello, Charles N. Habecker
  • Patent number: 4816457
    Abstract: Heterocyclic aminoethanols of the formula:Het--CHOH--CH.sub.2 --NH-aralkylwhere Het is a 6-10 membered N-heterocycle are disclosed. The compounds are useful as pharmaceuticals.
    Type: Grant
    Filed: June 30, 1987
    Date of Patent: March 28, 1989
    Inventors: John J. Baldwin, Joseph Atkinson, David E. McClure
  • Patent number: 4816477
    Abstract: The compounds of the following structural formula (I) ##STR1## ar 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase inhibitors and useful as antihypercholesterolemic agents for the treatment of disease in which the inhibition of cholesterol biosynthesis would be useful, such as arteriosclerosis, hyperlipidemia and familial hypercholesterolemia.
    Type: Grant
    Filed: May 26, 1987
    Date of Patent: March 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Narindar N. Girotra, Shu S. Yang, Donald W. Graham
  • Patent number: 4816469
    Abstract: Novel 5-amino or substituted amino 1,2,3-triazoles are disclosed as having anticoccidial activity. The compounds are useful for controlling coccidiosis when administered in minor quantities to animals, in particular to poultry, usually in admixture with animal sustenance.
    Type: Grant
    Filed: November 6, 1987
    Date of Patent: March 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Richard J. Bochis, Richard L. Tolman, Elbert Harris
  • Patent number: 4814501
    Abstract: Pyrolysis of substituted salicylate O(N,N-dialkyl)thiocarbamates yielded the corresponding N,N-dialkyl-2-(methylthio)benzamide. Similarly, substituted 6-azasalicylate O(N,N-dialkyl)thiocarbamates yielded the corresponding N,N-dialkyl-2-(methylthio)-6-aza-benzamide.
    Type: Grant
    Filed: December 28, 1987
    Date of Patent: March 21, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Bruce E. Witzel, Robert K. Baker, Philippe L. Durette, Robert A. Frankshun
  • Patent number: 4814452
    Abstract: An enantioselective synthesis of 1,3,4,6,7,12b(S)-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-one provides a key intermediate for the preparation of the .alpha..sub.2 -adrenergic antagonist (2R,12bS)-N-(1,3,4,6,7,12-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl) -N-methyl-2-hydroxyethanesulfonamide hydrochloride, useful as an anti-depressant.
    Type: Grant
    Filed: July 3, 1986
    Date of Patent: March 21, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ralph P. Volante, Edward Corley, Ichiro Shinkai
  • Patent number: 4814183
    Abstract: The instant invention is directed to a drug delivery device for the controlled release of beneficial agents and drugs into an environment of use comprising:(A) a core composition comprising(a) a water insoluble, non-diffusible charged resin entity, and(b) a diffusible, water soluble ionizable therapeutically active ingredient carrying the same charge as said resin entity; and(B) a substantially imperforate water-insoluble wall surrounding said core composition, prepared from a semipermeable material substantially impermeable to the core composition and permeable to the passage of an external fluid in the environment of use, with said wall having a hole(s) for release of the therapeutic agent through the water insoluble wall.
    Type: Grant
    Filed: August 31, 1987
    Date of Patent: March 21, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Gaylen M. Zentner
  • Patent number: 4812463
    Abstract: Alkane sulfonamides with an electron withdrawing function .beta. to the sulfonamide group are topically effective carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure and glaucoma.
    Type: Grant
    Filed: December 10, 1987
    Date of Patent: March 14, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Samuel L. Graham, Thomas H. Scholz
  • Patent number: 4810725
    Abstract: 1-Aryloxy-3-(substituted aminoalkylamino)-2-propanols and pharmaceutically acceptable salts thereof have .beta.-adrenergic blocking activity with some cardioselectivity and hence are useful as anti-hypertensive, antianginal, antiarrhythmic and cardioprotective agents and in the treatment of elevated intraocular pressure such as glaucoma.
    Type: Grant
    Filed: October 14, 1986
    Date of Patent: March 7, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Sandor L. Varga
  • Patent number: 4808595
    Abstract: Furopyridine sulfonamides are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure and disorders associated therewith such as glaucoma.
    Type: Grant
    Filed: May 5, 1988
    Date of Patent: February 28, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Jacob M. Hoffman, Jr.
  • Patent number: 4808718
    Abstract: Novel fused polycyclic and bridged compounds are disclosed which are useful as calcium entry blockers.
    Type: Grant
    Filed: May 6, 1986
    Date of Patent: February 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Wasyl Halczenko, Brian T. Phillips